Castration-resistant Clinical Trials in Los Angeles, California
27 recruitingLos Angeles, California
Showing 1–20 of 27 trials
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled96 locationsNCT05489211
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled80 locationsNCT06863272
Recruiting
Phase 1
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8+2 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT05398302
Recruiting
Phase 1Phase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled136 locationsNCT07225946
Recruiting
Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled168 locationsNCT07164443
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 2
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Kyntra Bio75 enrolled20 locationsNCT06842498
Recruiting
Phase 2
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Zenith Epigenetics200 enrolled31 locationsNCT04986423
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1Phase 2
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science99 enrolled1 locationNCT06615752
Recruiting
Phase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
Breast CancerColorectal, CancerGastric Cancer+19 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 2
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Castration-resistant Prostate Cancer
Edwin Posadas, MD100 enrolled3 locationsNCT05534646
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-Resistant Prostatic Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
Gastric CancerNon-small Cell Lung Cancer (NSCLC)Cervical Cancer+11 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 1Phase 2
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Metastatic Castration-resistant Prostate Cancer
FutureChem26 enrolled4 locationsNCT05458544